The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    14 injured as escalator reverses at Sunae Station in Bundang

  • 3

    Gov't to launch intensive crackdown against foreigners committing drug crimes

  • 5

    Korea falls to Italy in FIFA U-20 World Cup semifinals

  • 7

    Netflix's new original 'Bloodhounds' to deliver cathartic action

  • 9

    INTERVIEWSpaceX's Starlink in Kyiv is wake-up call for Seoul

  • 11

    'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film

  • 13

    Billy Graham Seoul Crusade celebrates 50th anniversary

  • 15

    Home gardening boom inspires plant adoption, specialized care services for leafy companions

  • 17

    Yoon's labor reform drive sputters as umbrella union exits talks

  • 19

    Tom Cruise to visit Seoul on June 29 to promote 'Mission: Impossible 7'

  • 2

    RM to attend Seoul festival to mark BTS' 10th anniv.

  • 4

    Dog meat traders condemn first lady, animal rights groups' push for ban

  • 6

    Ad or song?: Coca-Cola Zero ad featuring NewJeans becomes marketing blueprint

  • 8

    Robot to conduct orchestra for 1st time in Korea

  • 10

    PHOTOSSubway escalator accident

  • 12

    Dollar remittance, foreign exchange rules to be eased

  • 14

    NATO chief to chair emergency Ukraine meeting over dam

  • 16

    Canada wildfires shroud New York in apocalyptic haze

  • 18

    Korean businesses seek tougher punishments for industrial espionage

  • 20

    White Cube to open space in Seoul

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
Sat, June 10, 2023 | 05:59
Retail & Food
Korean biosimilars tap into US market
Posted : 2017-08-08 16:56
Updated : 2017-08-08 19:02
Park Jae-hyuk
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link
Celltrion's headquarters in Incheon / Courtesy of Celltrion
Celltrion's headquarters in Incheon / Courtesy of Celltrion

Celltrion's Herzuma set to debut next year


By Park Jae-hyuk

Korean biosimilars have begun to expand their presence in the U.S. market.

Domestic pharmaceutical firms such as Celltrion and Samsung Bioepis are expected to vie with global competitors, as well as each other, with their high-quality biosimilars based on enhanced technical skills.


According to industry officials, Tuesday, the U.S. Food and Drug Administration (FDA) accepted a biologics license application (BLA) for Celltrion's cancer treatment Herzuma last week.

Herzuma is a cheaper biosimilar copy of Herceptin, which has been sold by Swiss pharmaceutical giant Roche and was developed by Roche-owned Genentech. Herceptin's global sales surpassed $7 billion last year.

Celltrion submitted the BLA for the biosimilar drug in May. After a 60-day review in accordance with the law, the FDA officially accepted the application. The final approval of the drug is expected to be made in the first half of next year.

Herzuma was approved in Korea in January 2014 and will hit the shelves toward the end of the year. Celltrion applied for licenses to sell the drug in Europe and Japan as well.

Given its Remsima, a treatment for autoimmune diseases, has been marketed in the United States under the name of Inflectra, the Incheon-based company expects to expand its presence in the world's largest pharmaceutical market.

As the first Korean biosimilar approved in the U.S., Remsima has increased its market share since last December, according to the company. The application for Truxima, another Celltrion biosimilar, has been accepted by FDA as well.

"We will try our best to offer treatments to more patients in the U.S.," Celltrion CEO Kee Woo-sung was quoted as saying. The firm also said its Herzuma will be distributed there by global pharmaceutical firm Teva.

In addition to Celltrion, Samsung Bioepis has begun to tap into the U.S. market.

Its biosimilar drug Renflexis was also launched in the U.S. last week following the approval of FDA three months ago. The immunology medicine is a biosimilar copy of Janssen Biotech's blockbuster Remicade.

Renflexis has been marketed by Samsung Bioepis's global partner Merck & Co. at a wholesale acquisition price of $753.39, 35 percent cheaper than the current listing price of Remicade.

"Samsung Bioepis has been able to rank with global pharmaceutical giants in the world's largest market following the launch of Renflexis," Samsung Bioepis CEO Ko Han-sung said in a statement. "We expect more patients will benefit from the drug."

Meanwhile, Celltrion founder Seo Jung-jin has become the nation's 10th richest stockholder, thanks to the achievement of the biosimilars. He is the second self-made figure to be included in the top 10 list, along with Netmarble Games chief Bang Joon-hyuk.

According to Chaebul.com, Seo held shares worth 2.4 trillion won ($2.13 billion) as of last week, after Celltrion Healthcare was listed on the KOSDAQ market.

Both Celltrion and Celltrion Healthcare were established by Seo. While the former develops biosimilars, the latter exclusively ships the drugs overseas.

Emailpjh@koreatimes.co.kr Article ListMore articles by this reporter
 
wooribank
Top 10 Stories
1Rising minimum wage burdens small biz owners: survey Rising minimum wage burdens small biz owners: survey
2IPO market regains vigor on bullish KOSPI IPO market regains vigor on bullish KOSPI
3Resurging household loans pose challenge for BOK's rate policy Resurging household loans pose challenge for BOK's rate policy
4SPC bolsters PR activities in US SPC bolsters PR activities in US
5OpenAI explores investment opportunities in Korean startups: Sam AltmanOpenAI explores investment opportunities in Korean startups: Sam Altman
6China reaches out to Korean Assembly to counterweigh Yoon's bet on US China reaches out to Korean Assembly to counterweigh Yoon's bet on US
7Japanese business leaders pledge to support Busan's Expo bidJapanese business leaders pledge to support Busan's Expo bid
8S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders
9Hyundai Motor partners with Spider-Man animation to envision future mobility Hyundai Motor partners with Spider-Man animation to envision future mobility
10Yoon's $40,000 GNI by 2027 goal seems unlikely prospectYoon's $40,000 GNI by 2027 goal seems unlikely prospect
Top 5 Entertainment News
1China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve
2[INTERVIEW] CIX talks about team chemistry, youth theme INTERVIEWCIX talks about team chemistry, youth theme
3Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt' Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt'
4Netflix's new original 'Bloodhounds' to deliver cathartic actionNetflix's new original 'Bloodhounds' to deliver cathartic action
5'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film 'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film
DARKROOM
  • Turkey-Syria earthquake

    Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group